Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Opinion & Analysis Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

Opinion & Analysis (TSXV:CLAS.H)

    Buzz on the Bullboards: Mining Heats Up as Healthcare Makes Headlines

    Stockhouse Editorial March 11, 2021

    Buzz on the Bullboards: In the COVID Fallout, New Players Emerge

    Stockhouse Editorial March 4, 2021

    Buzz on the Bullboards: Eyes on Cannabis Rebound

    Omri Wallach May 21, 2020

    Buzz on the Bullboards: Big Last-Minute Moves

    Omri Wallach December 12, 2019

    New Cannabis CBD Patent Issued to Kalytera

    Stockhouse Editorial July 4, 2018

    New Cannabis CBD Patent Issued to Kalytera

    Stockhouse Editorial April 23, 2018

    Junior explorer surges on gold assays

    Sean Mason June 21, 2012